Shares of CureVac N.V. (CVAC) are rising more than 14% Friday morning after the company announced positive preliminary data from the early-stage studies of COVID-19 and Flu vaccine candidates.
Results from the Phase 1 study showed that the company’s Covid-19 vaccine candidate CV0501, successfully boosted antibody titers against BA.1 and the wild type variants, and was generally well tolerated across all tested dose groups.
Flu vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain, even at lowest dose, the company said.
CureVac plans to advance these vaccine candidates to the next stage of study in this year.
CVAC is at $7.29 currently. It has traded in the range of $5.63-$31.84 in the last 1 year.
Source: Read Full Article
-
Can Next Bitcoin Halving Push BTC Price To $148,000 By July 2025? Pantera Capital Thinks So
-
Dollar Tree Falls On Lower Quarterly Profit, Outlook Shy Of Estimates
-
The Bitcoin Comeback: Will It Retake $28K Before August Ends?
-
Hibbett Shares Rally On Better-than-estimated Earnings, Increased Outlook
-
Coinbase CEO Thinks Brazil and Argentina Should ‘Consider Moving to Bitcoin’